Skip to main content

Table 3 Efficacy of Vedolizumab on pediatric inflammatory bowel disease

From: Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review

IBD type

Outcome measures

Number of studies

Overall[percentage; 95% CI]

CD

Remission

2 weeks

2

8/36[22;11–42]

6 weeks

4

19/75[25;17–37]

12 weeks

1

26/71[37;25–48]

14 weeks

6

25/85[28;18–37]

22 weeks

3

17/53[32;19–44]

24 weeks

1

32/73[44;32–55]

30 weeks

2

12/24[52;10–93]

1 year

3

43/92[46;36–57]

Response

6 weeks

1

5/15[33;9–57]

14 weeks

4

20/39[52;37–67]

22 weeks

1

9/15[60;35–85]

30 weeks

1

6/13[46;19–73]

1 year

1

5/10[50;19–81]

CS-free clinical remission

6 weeks

1

1/15[7;-6–19]

12 weeks

1

24/71[34;23–45]

14 weeks

3

5/37[14;3–29]

22 weeks

3

12/47[26;11–36]

24 weeks

1

30/73[41;30–52]

26 weeks

1

5/7[71;38–105]

38 weeks

1

0/6[0;NA]

1 year

1

35/78[45;34–56]

UC/IBD-U

Remission

2 weeks

2

11/27[41;22–59]

6 weeks

4

25/70[36;10–57]

12 weeks

1

37/79[47;36–58]

14 weeks

6

52/101[48;31–65]

22 weeks

3

24/45[53;36–73]

24 weeks

1

42/79[53;42–64]

30 weeks

2

21/31[68;52–84]

1 year

3

50/112[45;35–54]

Response

2 weeks

1

1/5[20;–15–55]

6 weeks

1

1/4[25;–17–67]

14 weeks

3

30/44[69;53–84]

22 weeks

1

2/4[50;1–99]

30 weeks

1

18/23[78;61–95]

1 year

1

15/21[71;52–91]

CS-free clinical remission

6 weeks

1

0/5[0;NA]

12 weeks

1

35/79[44;33–55]

14 weeks

3

17/44[39;17–51]

22 weeks

3

26/45[58;44–73]

24 weeks

1

39/79[49;38–60]

26 weeks

1

7/9[78;51–105]

38 weeks

1

4/5[80;45–115]

1 year

1

33/81[41;30–51]

  1. Abbreviations: IBD, inflammatory bowel disease, CD Crohn’s disease, UC ulcerative disease, IBD-U inflammatory bowel disease unspecified, CS corticosteroids